☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC reject rimonobant

The Scottish Medicines Consortium (SMC) has rejected rimonobant (Acomplia®) for use on the NHS in Scotland.

The recommendation states that the economic case has not been demonstrated although it also indicates that a resubmission is likely.

Rimonobant has already been identified as having a lower place in therapy by the Midlands Therapeutic Review and Advisory Committee and it was previously recommended as a fourth line option when it was launched.

Action: Until an economic case is demonstrated it would be sensible to restrict prescribing of rimonobant to patients who have already started treatment and are achieving weight loss.

Share 'SMC reject rimonobant' by emailShare 'SMC reject rimonobant' on FacebookShare 'SMC reject rimonobant' on TwitterShare 'SMC reject rimonobant' on LinkedInShare 'SMC reject rimonobant' on reddit


No Comments to “SMC reject rimonobant”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.